WilmerHale represented the underwriters in the public offering of 20,355,000 shares of common stock of Inovio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, at a public offering price per share of $8.50. The shares of common stock sold reflected the full exercise of the underwriters’ option to purchase additional shares, and the gross proceeds to the company were approximately $173 million, before deducting underwriting discounts and offering expenses. The offering priced on January 20, 2021 and closed on January 25, 2021.

The WilmerHale team advising the underwriters consisted of Lisa Firenze, Bruce Manheim, Colleen Superko, Sean Linnehan and Elizabeth Brasher.